{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T05:31:22Z","timestamp":1740807082838,"version":"3.38.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","brachyjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.brachy.2024.10.011","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T20:17:16Z","timestamp":1735676236000},"page":"223-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Escalating the dose of high-dose-rate brachytherapy combined with external beam radiotherapy improves the disease control rate in patients with high- or very-high-risk prostate cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-2933","authenticated-orcid":false,"given":"Takaya","family":"Inagaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Iwahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Naka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riki","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuki","family":"Shimono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azusa","family":"Awaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6103-6320","authenticated-orcid":false,"given":"Yasuo","family":"Kohjimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Sonomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2024","key":"10.1016\/j.brachy.2024.10.011_bib0001"},{"key":"10.1016\/j.brachy.2024.10.011_bib0002","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1158\/1055-9965.EPI-23-0754","article-title":"Cancer prevalence projections in Japan and decomposition analysis of changes in cancer burden, 2020\u20132050: a statistical modeling study","volume":"32","author":"Nguyen","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.brachy.2024.10.011_bib0003","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the Prostate Cancer Intervention versus Observation Trial (PIVOT)","volume":"77","author":"Wilt","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253081","article-title":"Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: nationwide, population-based study","volume":"16","author":"Godtman","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.brachy.2024.10.011_bib0005","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","article-title":"Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review","volume":"77","author":"Moris","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0006","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase iii trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0007","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2022.08.030","article-title":"The fraction size sensitivity of late genitourinary toxicity: analysis of alpha\/beta (\u03b1\/\u03b2) ratios in the CHHiP trial","volume":"115","author":"Brand","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.10.011_bib0008","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0009","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2018.10.013","article-title":"Ten-year survival after high-dose-rate brachytherapy combined with external beam radiation therapy in high-risk prostate cancer: a comparison with the Norwegian SPCG-7 cohort","volume":"132","author":"Wedde","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0011","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ijrobp.2020.11.008","article-title":"Long-term results of NRG Oncology\/RTOG 0321: a phase ii trial of combined high dose rate brachytherapy and external beam radiation therapy for adenocarcinoma of the prostate","volume":"110","author":"Hsu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.10.011_bib0012","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1200\/JCO.2016.72.0466","article-title":"Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology\/Cancer Care Ontario joint guideline update","volume":"35","author":"Chin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0013","unstructured":"Schaeffer EM, Srinivas S, Adra Nabil, et al. NCCN Guidelines Version 4.2024 Prostate Cancer. 2024. Available at: https:\/\/www.nccn.org. Accessed 23 June 2024."},{"key":"10.1016\/j.brachy.2024.10.011_bib0014","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"GEC-ESTRO ACROP prostate brachytherapy guidelines","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0015","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","article-title":"Prostate alpha\/beta revisited an analysis of clinical results from 14 168 patients","volume":"51","author":"Dasu","year":"2012","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.brachy.2024.10.011_bib0016","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2\u202f=\u202f1.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.10.011_bib0017","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated radiation therapy for localized prostate cancer: An ASTRO, ASCO, and AUA evidence-based guideline","volume":"36","author":"Morgan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0018","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2013.05.002","article-title":"GEC\/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update","volume":"107","author":"Hoskin","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0019","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ijrobp.2008.02.055","article-title":"High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer","volume":"72","author":"Sato","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2024.10.011_bib0020","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.3390\/cancers3033585","article-title":"Efficacy and safety of high-dose-rate brachytherapy of single implant with two fractions combined with external beam radiotherapy for hormone-na\u00efve localized prostate cancer","volume":"3","author":"Noda","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.brachy.2024.10.011_bib0021","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41598-021-04233-4","article-title":"Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9\u201310 clinical localized prostate cancer","volume":"12","author":"Yamazaki","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.brachy.2024.10.011_bib0022","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2017.06.012","article-title":"High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes","volume":"124","author":"Vigneault","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0023","series-title":"TNM classification of malignant tumours","first-page":"191","author":"Brierley","year":"2017"},{"key":"10.1016\/j.brachy.2024.10.011_bib0024","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"year":"2024","series-title":"U.S. Department of Health and Human Services: Common terminology criteria for adverse events (CTCAE) v5.0","key":"10.1016\/j.brachy.2024.10.011_bib0025"},{"key":"10.1016\/j.brachy.2024.10.011_bib0026","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.radonc.2015.05.011","article-title":"What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation","volume":"115","author":"Zaorsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0027","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2008.11.013","article-title":"Urethral stricture following high dose rate brachytherapy for prostate cancer","volume":"91","author":"Sullivan","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0028","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.brachy.2021.02.002","article-title":"Reduction of toxicity in brachytherapy using a new technique","volume":"20","author":"Miyazaki","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2024.10.011_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110024","article-title":"Prospective study of HDR brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach","volume":"190","author":"Gomez-Iturriaga","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1200676","article-title":"Dose outside of the prostate is associated with improved outcomes for high-risk prostate cancer patients treated with brachytherapy boost","volume":"13","author":"Shortall","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0031","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0022-5347(05)65177-4","article-title":"Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis","volume":"167","author":"Heidenreich","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0032","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase iii randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0033","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.clon.2014.06.016","article-title":"Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses","volume":"26","author":"Schmidt-Hansen","year":"2014","journal-title":"Clin Oncol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0034","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.21037\/tau-22-396","article-title":"Management of patients with advanced prostate cancer in Japan: \u201creal-world\u201d consideration of the results from the Advanced Prostate Cancer Consensus Conference","volume":"11","author":"Fujita","year":"2022","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.brachy.2024.10.011_bib0035","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00259-021-05296-1","article-title":"Prospective comparison of 18F-PSMA-1007 PET\/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate-and high-risk prostate cancer","volume":"48","author":"Malaspina","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472124004422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472124004422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:37:59Z","timestamp":1740746279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472124004422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1538472124004422"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2024.10.011","relation":{},"ISSN":["1538-4721"],"issn-type":[{"type":"print","value":"1538-4721"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Escalating the dose of high-dose-rate brachytherapy combined with external beam radiotherapy improves the disease control rate in patients with high- or very-high-risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2024.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Brachytherapy Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}